Pursuant to Regulation 33(3)(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Lincoln Pharmaceuticals has informed that the Company will continue to submit Quarterly /Year to Date Standalone and Consolidated Financial Results for the Financial Year 2018-19.
The above information is a part of company’s filings submitted to BSE.